Simon Crabb outlines the final results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic urothelial cancer, and discusses them in light of the recent JAVELIN Bladder 100 and ATLAS trials. This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Results from the ATLANTIS trial platform indicate that rucaparib could play a role in the maintenance treatment of metastatic urothelial carcinoma with a DNA repair deficiency that has responded to first-line platinum-based chemotherapy.

Phase 2 TRITON2 study data suggest that men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 mutation may benefit from treatment with the PARP inhibitor rucaparib.

Rucaparib has been granted accelerated approval for use in men with a germline and/or somatic BRCA mutation who have previously received androgen receptor inhibitor therapy and taxane-based chemotherapy.

Results of the phase 2 ATLAS trial do not support use of the PARP inhibitor rucaparib in patients with recurrent, locally advanced, or metastatic urothelial carcinoma, the investigators have reported.

medwireNews : The EMA has adopted a positive opinion for use of the PARP inhibitor rucaparib in patients with progressive or relapsed ovarian cancer.

By Lynda Williams medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group See also: Rucaparib authorization recommended for relapsed, progressive ovarian cancer ARIEL3 demonstrates maintenance rucaparib benefit for advanced platinum-sensitive ovarian cancer

Maintenance therapy with the PARP inhibitor rucaparib offers significantly longer progression-free survival than placebo for women with advanced platinum-sensitive ovarian cancer, indicate ARIEL3 trial findings reported at the ESMO 2017 Congress in Madrid, Spain.

This translated to a significant association between PARP inhibitor use and pancytopenia for the drug class as a whole (reporting odds ratio [ROR]=5.5) and for the five individual PARP inhibitors assessed, namely talazoparib (ROR=17.4), veliparib (ROR=8.2), niraparib (ROR=6.8), olaparib (ROR=5.3), and rucaparib (ROR=2.2).

Petros Grivas explains why the story of PARP inhibitors in advanced urothelial carcinoma is not quite finished yet despite the negative results of the ATLAS trial of rucaparib in this setting (4:45).

The announcement follows the US FDA’s decision to approve both olaparib and rucaparib in a similar indication . medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2020 Springer Healthcare Ltd, part of the Springer Nature Group

The test is also able to identify alterations in BRCA1 or BRCA2 in metastatic castration-resistant prostate cancer patients who may be suitable for rucaparib treatment.  

The study was powered to investigate rucaparib in all-comers (regardless of the presence or not of DNA damage response mutations), but also in the subset of patients with high genome-wide loss of heterozygozity.